Connect with us

Biotechnology

Boston Scientific Announces Results For Second Quarter 2020

Avatar

Published

on

MARLBOROUGH, Mass., July 29, 2020 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated sales of $2.003 billion during the second quarter of 2020. This represents a decline of (23.9) percent on a reported basis, (23.1) percent on an operational1 basis and (28.7) percent on an organic2 basis, all compared to the prior year period. The company reported a GAAP loss of $147 million or $(0.11) per share (EPS), compared to GAAP earnings of $154 million or $0.11 per share a year ago, and achieved adjusted earnings per share of $0.08 for the period, compared to $0.39 a year ago.

“We remain focused on the safety of our team, our customers and the patients they serve, and were pleased to see the business recovering over the course of the quarter,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “With a strong pipeline of differentiated products and an agile global team, we’ll continue to execute on our strategy and make prudent decisions to position us for success as deferred procedures resume.”

Second quarter financial results and recent developments:

  • Reported a GAAP loss of $(0.11) per share. Achieved adjusted earnings per share of $0.08. The company did not provide second quarter sales and EPS guidance due to ongoing uncertainty associated with the scope and duration of the COVID-19 pandemic.
  • Second quarter sales declined in each of our reportable segments4, compared to the prior year period:
    • MedSurg: (29.6) percent reported, (29.1) percent operational and (28.4) percent organic
    • Rhythm and Neuro: (33.2) percent reported, (32.7) percent operational and (33.4) percent organic
    • Cardiovascular: (18.7) percent reported, (17.6) percent operational and (25.3) percent organic
  • Second quarter regional5 sales declined, compared to the prior year period:
    • U.S.: (28.4) percent reported and operational
    • EMEA (Europe, Middle East and Africa): (27.2) percent reported and (25.6) percent operational
    • APAC (Asia-Pacific): (14.8) percent reported and (14.0) percent operational
    • Emerging Markets3: (19.7) percent reported and (14.6) percent operational
  • Received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device which is indicated to reduce the risk of stroke in patients with non-valvular atrial fibrillation. This next-generation implant is the first LAAC device that can be fully recaptured, repositioned and redeployed in the left atrial appendage, with additional design features to enhance safety and performance while treating a wider range of patient anatomies than the previous WATCHMAN LAAC device.
  • Received FDA approval for the SYNERGY™ XD Bioabsorbable Polymer (BP) Drug-Eluting Stent (DES) System, the next-generation SYNERGY BP-DES platform with the only 48 mm length DES available in the U.S. and enhanced deliverability features to enable improved arterial navigation in percutaneous coronary intervention (PCI) cases. The system was recently launched in Japan following approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
  • Received FDA 510(k) clearance and began limited market release for the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a new, long-term diagnostic device implanted in patients to detect arrythmias associated with conditions such as atrial fibrillation (AF), cryptogenic stroke and syncope. The LUX-Dx ICM System can be programmed remotely and have settings adjusted without requiring patients to visit their physician’s office and is designed with a dual-stage algorithm that detects and then verifies potential arrhythmias before an alert is sent to clinicians.
  • Received approval for the Eluvia™ Drug-Eluting Vascular Stent System from China’s Center for Medical Device Evaluation and will begin a limited market release by the end of the year. Also announced results of a sub-study of patients from the IMPERIAL trial who were treated with the Eluvia stent during the 2020 Vascular Interventional Advances (VIVA) Late-Breaking Clinical Trials Livestream event. Data demonstrated the Eluvia stent offers durable and consistent results in complex and long lesions, with an average lesion length of 162.8 mm and that patients treated with the Eluvia stent had a 77.2% Kaplan-Meier primary patency rate, a 13.6% clinically-driven target lesion revascularization rate and no stent thrombosis, despite long, heavily calcified lesions.
  • Received CE Mark and began limited European release for the INTELLANAV STABLEPOINT™ Ablation Catheter enabled with DIRECTSENSE™ Technology. This first-of-its-kind catheter combines measures of mechanical contact, or contact force, with local impedance to provide insight into the cardiac tissue’s response to ablation.
  • Received Centers for Medicare & Medicaid Services (CMS) approval for a new transitional pass-through (TPT) payment category to describe single-use endoscopes, including the EXALT™ Model D Single-Use Duodenoscope, to facilitate Medicare beneficiary access to the advantages of new and innovative devices by allowing for adequate payment while cost data is collected, starting July 1, 2020. The EXALT™ duodenoscope is the world’s first and only single-use, flexible duodenoscope cleared by the U.S. Food and Drug Administration (FDA), which eliminates the risk of infection from inadequate scope reprocessing between procedures.
  • Presented positive findings from the largest reported clinical experience to date with the LOTUS Edge™ Aortic Valve System at TVT Connect. Data from a pre-specified interim analysis of the first 50 patients enrolled in the European RESPOND EDGE post-market registry demonstrated no reports of mortality, no repeat procedures for valve-related dysfunction or re-hospitalization for valve-related symptoms and excellent valve hemodynamics, the lowest PVL rates in this valve category and a reduced permanent pacemaker implantation rate in line with competitive valves in real-world experience.
  • Commenced enrollment of the FROZEN-AF investigational device exemption (IDE) clinical trial which will evaluate the safety and effectiveness of the POLARx™ Cryoablation System for the treatment of paroxysmal atrial fibrillation (AF), an intermittent form of AF which causes an irregular and often abnormally fast heart rate.
  • Announced at HRS 2020 Science final results from the UNTOUCHED study of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System, the only FDA-approved implantable defibrillator without wires touching the heart, demonstrating high efficacy and safety of the device and a lower rate of inappropriate shock than many similar devices. Also presented as a late-breaking clinical trial at the virtual meeting were results from the investigator-sponsored PRAETORIAN trial confirming that the S-ICD can be the preferred therapy choice for the majority of ICD-indicated patients without a need for pacing.
  • Published a meta-analysis of 1,011 prostate cancer patients in The Journal of the American Medicine Association (JAMA) Network Open which found that placing SpaceOAR Hydrogel® before radiation is an effective preventative strategy to reduce treatment-induced rectal complications. Each year, more than 1.1 million men are diagnosed with prostate cancer worldwide and approximately 400,000 men will undergo prostate radiotherapy. Recently, SpaceOAR surpassed 100,000 patients treated worldwide.
  • Announced The Lancet Neurology publication of the INTREPID study—a double-blind, randomized study evaluating the Vercise™ Deep Brain Stimulation (DBS) system for Parkinson’s disease. One-year results demonstrated a significant 51% improvement in motor symptoms (UDPRS III scores) compared to pre-surgery screening and six additional hours of ON time – or daily symptom control – over medication.
  • Launched a multi-year program to combat racism, inequity and injustice, including $3.5 million in philanthropic commitments, focused on five pillars: community, economic empowerment, education, healthcare disparities and government/legislative change.
  • Increased financial flexibility by completing a public offering of $1.7 billion aggregate principal amount of Senior Notes, as well as completing an approximately $2.0 billion public offering of common stock and mandatory convertible preferred stock, and using a portion of the proceeds of both offerings to repay borrowings under our revolving credit facility and a significant portion of our pre-payable bank debt.

1. Operational revenue growth excludes the impact of foreign currency fluctuations.

2. Organic revenue growth excludes the impact of foreign currency fluctuations and sales from the recent acquisitions of Vertiflex, Inc. and BTG plc (BTG), each with no prior year comparable sales. Organic revenue growth also excludes the impact of the divestiture of our global embolic microspheres portfolio, a transaction entered into in connection with obtaining the antitrust clearances required to complete the BTG transaction, as well as the Q2 divestiture of our intrauterine health franchise.

3. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.

4. We have three historical reportable segments comprised of Medical Surgical (MedSurg), Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments that generate revenues from the sale of medical devices (Medical Devices). As part of our acquisition of BTG on August 19, 2019, we acquired an Interventional Medicine business, which is now included in our Peripheral Interventions operating segment’s revenues from the date of acquisition.

5. As part of our acquisition of BTG on August 19, 2019, we acquired a specialty pharmaceuticals business (Specialty Pharmaceuticals). Subsequent to acquisition, Specialty Pharmaceuticals is now a stand-alone operating segment presented alongside our Medical Device reportable segments. Specialty Pharmaceuticals net sales are substantially U.S. based. Our chief operating decision maker (CODM) reviews financial information of our globally managed Specialty Pharmaceuticals operating segment at the worldwide level without further disaggregation into regional results. As such, Specialty Pharmaceuticals net sales are presented globally, and our Medical Devices reportable segments regional net sales results do not include Specialty Pharmaceuticals.

Net sales for the second quarter by business and region:

         

Change

   

Three Months Ended
June 30,

 

Reported
Basis

 

Less: Impact
of Foreign
Currency
Fluctuations

 

Operational
Basis

 

Less:
Impact of
Recent
Acquisitions /
Divestitures

 

Organic
Basis

(in millions)

2020

2019

         
                           
 

Endoscopy

$

348

$

470

 

(26.0)%

 

(0.5)%

 

(25.5)%

 

—%

 

(25.5)%

 

Urology and Pelvic Health

228

348

 

(34.5)%

 

(0.4)%

 

(34.1)%

 

(1.7)%

 

(32.4)%

 

MedSurg

576

818

 

(29.6)%

 

(0.5)%

 

(29.1)%

 

(0.7)%

 

(28.4)%

 

Cardiac Rhythm Management

351

498

 

(29.4)%

 

(0.6)%

 

(28.8)%

 

—%

 

(28.8)%

 

Electrophysiology

51

84

 

(39.2)%

 

(0.3)%

 

(38.9)%

 

—%

 

(38.9)%

 

Neuromodulation

122

204

 

(40.0)%

 

(0.3)%

 

(39.7)%

 

2.9%

 

(42.6)%

 

Rhythm and Neuro

525

786

 

(33.2)%

 

(0.5)%

 

(32.7)%

 

0.7%

 

(33.4)%

 

Interventional Cardiology

495

706

 

(29.9)%

 

(1.1)%

 

(28.8)%

 

—%

 

(28.8)%

 

Peripheral Interventions

340

320

 

6.0%

 

(1.0)%

 

7.0%

 

24.4%

 

(17.4)%

 

Cardiovascular

834

1,026

 

(18.7)%

 

(1.1)%

 

(17.6)%

 

7.7%

 

(25.3)%

 

Medical Devices4

1,935

2,631

 

(26.5)%

 

(0.8)%

 

(25.7)%

 

3.0%

 

(28.7)%

 

Specialty Pharmaceuticals5

68

n/a

 

n/a

 

n/a

 

n/a

 

n/a

 

n/a

Net Sales

$

2,003

$

2,631

 

(23.9)%

 

(0.8)%

 

(23.1)%

 

5.6%

 

(28.7)%

                                           
         

Change

   

Three Months Ended
June 30,

 

Reported
Basis

 

Less: Impact
of Foreign
Currency
Fluctuations

 

Operational
Basis

(in millions)

2020

2019

     
                   
 

U.S.

$

1,058

$

1,478

 

(28.4)%

 

—%

 

(28.4)%

 

EMEA

416

571

 

(27.2)%

 

(1.6)%

 

(25.6)%

 

APAC

410

481

 

(14.8)%

 

(0.8)%

 

(14.0)%

 

Latin America and Canada

51

101

 

(49.4)%

 

(6.3)%

 

(43.1)%

 

Medical Devices4

1,935

2,631

 

(26.5)%

 

(0.8)%

 

(25.7)%

 

Specialty Pharmaceuticals5

68

n/a

 

n/a

 

n/a

 

n/a

 

Net Sales

$

2,003

$

2,631

 

(23.9)%

 

(0.8)%

 

(23.1)%

                   
 

Emerging Markets3

$

255

 

$

318

 

(19.7)%

 

(5.1)%

 

(14.6)%

                   
 

Amounts may not add due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely.

   
 

Sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of recent aforementioned acquisitions / divestitures are not prepared in accordance with U.S. GAAP.

                         

Conference Call Information

Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. EDT. The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans and product performance, and the impact of the COVID-19 outbreak on the company’s results of operations. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Use of Non-GAAP Financial Information

A reconciliation of the company’s non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company’s use of these non-GAAP financial measures, is included in the exhibits attached to this press release.

CONTACT:

       

Media:

Kate Haranis

 

Investors:

Susie Lisa, CFA

 

508-683-6585 (office)

   

508-683-5565 (office)

 

Media Relations

   

Investor Relations

 

Boston Scientific Corporation

   

Boston Scientific Corporation

 

kate.haranis@bsci.com

   

BSXInvestorRelations@bsci.com

Use of Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (loss) and adjusted net income (loss) per share (EPS) that exclude certain amounts, operational net sales, which exclude the impact of foreign currency fluctuations and organic net sales, which exclude the impact of foreign currency fluctuations and the impact of recent aforementioned acquisitions and divestitures. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (loss) and adjusted net income (loss) per share we exclude certain charges (credits) from GAAP net income available to common stockholders. Amounts are presented after-tax at the company’s effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB Accounting Standards Codification section 740-270-30, “General Methodology and Use of Estimated Annual Effective Tax Rate.” Please refer to Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission or any Quarterly Report on Form 10-Q that we file thereafter for an explanation of each of these adjustments and the reasons for excluding each item.

The GAAP financial measures most directly comparable to adjusted net income (loss) and adjusted net income (loss) per share are GAAP net income (loss) and GAAP net income (loss) per share available to common stockholders.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. To calculate organic net sales growth rates, we remove the impact of recent aforementioned acquisitions with no prior period related net sales from operational net sales. In addition, to calculate organic net sales growth rates, we remove from prior year, sales from product lines that we divested. The GAAP financial measure most directly comparable to operational net sales and organic net sales is net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the accompanying schedules.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income (loss) and adjusted net income (loss) per share, operational net sales and organic net sales, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/boston-scientific-announces-results-for-second-quarter-2020-301101773.html

SOURCE Boston Scientific Corporation

Company Codes: NYSE:BSX

Source: https://www.biospace.com/article/releases/boston-scientific-announces-results-for-second-quarter-2020/?s=75

Biotechnology

Benefits of Purchasing Used Lab Equipment

Avatar

Published

on

In the laboratory industry, there can be a lot of pressure to always have the newest and latest technology. Due to concerns about having outdated or inefficient equipment, many professionals don’t even consider purchasing used equipment. However, there are numerous advantages to doing so. Here are some of the key benefits of purchasing used lab equipment to keep in mind next time you need to purchase equipment.


Financial Benefits

One of the most significant and obvious benefits of purchasing used lab equipment is that doing so can save you a lot of money. Used laboratory equipment is significantly less expensive than brand new models. Often laboratories can save up to 50 percent or more by purchasing quality second-hand equipment.

Because laboratory equipment is often one of the top expenses that laboratories incur, purchasing used can substantially reduce laboratory costs and free up some much-needed room in tight budgets.

 

Environmental Benefits

Large laboratory equipment can take up a lot of room in landfills and often contain toxic components such as lead or mercury. Such toxins can seep into the earth and contaminate groundwater over time. By purchasing used laboratory equipment rather than new, you can reduce the amount of equipment that ends up in landfills. Plus, you will also reduce the number of raw materials used to manufacture new equipment which will decrease your lab’s negative impact on the environment.

Increased Insight

Purchasing a new type of equipment right after it is released comes with some risks. When a piece of equipment is fresh on the market, there aren’t many reviews from past customers attesting to how well or poorly it operates.\

Used equipment, however, is far less risky. Because the equipment has been on the market for a while, there are likely plenty of reviews that you can reference and any potential issues have likely been well-documented. Just make sure to purchase from a reliable and trustworthy reseller that took the proper measures to ensure the equipment is in optimal operating condition.

Reduced Wait Time

If you need a piece of equipment in a short period of time, buying used is often the best option. Many manufacturers have long wait times that can require you to wait for several weeks or even months before the equipment will arrive. If you have deadlines you need to meet, that simply won’t do. In cases when you need equipment in a timelier manner, used equipment is already built and ready to go so you often only have to wait for shipping.


 

Source: Christina Duron is a freelance writer for multiple online publications where she can showcase her affinity for all things digital. She has focused her career around digital marketing and writes to explore topics that spark her interest.

 

Continue Reading

Biotechnology

CYIOS CORP’S RECEIVES APPROVAL TO SELL ITS SANITIZER PRODUCTS ON AMAZON.COM

Avatar

Published

on

Deerfield Beach, Florida, November 23, 2020 – OTC PR WIRE — CYIOS Corp. (OTC US: CYIO), a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, is pleased to announce it has received approval from Amazon to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category.  Products to be sold on Amazon.com will include the My-shield triple play sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete.  Clinical data from these studies conducted on this trio of My-shield sanitizing products have shown long lasting sanitizer protection and effectiveness against a surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes.

John O’Shea CYIO’s Chairman stated, “We are pleased to have received this approval to sell various My-shield sanitizing products in Amazon’s Personal Safety and Household category.  Our strategy continues to be on developing market and distribution opportunities around a Triple Play of sanitizing products which have recently undergone clinical studies for effectiveness including My Shield Hand Sanitizer, My-shield Surface Cleaner and My-shield Laundry Complete. During the six week period of time we had to undergo for the approval process within this product category, several of the My-shield Zetrisl® based sanitizer products had completed lengthy clinical testing in a laboratory setting and showed effectiveness against a CDC recognized surrogate virus for SARS-CoV-2 on skin, hard surfaces, fabrics and clothes.  Results of which are posted here:  Zetrisil-The-Total-Covid-19-Solution

Approval on Amazon gives the Company an additional platform for selling direct to consumers, which complements our recently announced launch with RangeMe giving us direct access to thousands of retail purchasing managers on their B2B platform. As we enter the holiday season, keep an eye out for valuable holiday specials, product marketing and advertising on the My-shield Triple Play and our “24” Brand Hand sanitizer which is also Zetrisl® powered.  We believe giving the gift of safety and security with these long-lasting clinically proven sanitizers for effectiveness is a terrific and thoughtful holiday gift”.

About Zetrisil: Zetrisil®-based technologies are a family of proprietary silicon-based virus killing agents that reduce the presence of the virus from the hands, hard surfaces, fabric and most clothing environments.  Zetrisil® effectively protects and/or “shields” the area that “24” Brand hand sanitizer and My-shield products are applied to from bacterial contamination for an extended period of time after application. Made with non-alcohol, Benzalkonium Chloride (BZK), My-shield® and 24 Brand sanitizers are a safer alternative to Alcohol-based hand sanitizers which can be absorbed into the bloodstream, are flammable, and are only proven effective for a few minutes after each application.  These factors make traditional alcohol-based hand sanitizers a less than optimal choice particularly for families with children and/or for those out and about in public.  Because Zetrisil® is safer than traditional agents and remains on the skin for several hours, people are protected longer without the need for frequent applications of sanitizer ― all without the toxicity and flammability concerns of alcohol-based sanitizers.  The recent clinical testing data is powerful and proven evidence of the effectiveness of these products.

CONTACT INFORMATION

info@choicewellnessbrands.com

Investors are encouraged to follow CYIOS using:

www.twitter.com/cyioscorp

https://www.instagram.com/choicewellnessbrands/

https://www.linkedin.com/company/choice-wellness

https://www.facebook.com/choicewellnessbrands/

About ChoiceWellness, Inc:

ChoiceWellness, Inc. is a health and wellness company that has brought to market the DR’s CHOICE line of products, as well as the “24” Brand Hand Sanitizer products.  DR’s CHOICE was developed with a mission to offer Doctors and Medical Practitioners their own Professional Grade CBD BRAND with a suite of products they could stand behind and be confident to offer to their patients.  Our customers can be assured that DR’s CHOICE CBD products have gone through the highest scrutiny of testing for purity, potency and quality. DR’s Choice products have been brought to market for Doctors and Medical Professionals seeking a better solution for patients suffering from pain, inflammation, anxiety or other persistent symptoms.  For more information please visit www.choicewellnessbrands.com

About CYIOS Corporation

CYIOS Corporation is a publicly traded company focused on developing and marketing specialty branded products in the Health and Wellness markets, including the “DR’s CHOICE” and “24” brand of products. The team has in-depth knowledge of the health and wellness markets, financial services industry, medical and health services, and blockchain. The Company looks to develop, distribute, and license proprietary products as well as evaluate potential acquisition opportunities. Further, the Company continues to seek and evaluate attractive business opportunities and to leverage its resources and expertise to build a diversified, sustainable business model.  For more information please visit www.cyioscorporation.com

FORWARD-LOOKING STATEMENTS: This release contains “forward-looking statements.” Forward-looking statements also may be included in other publicly available documents issued by the Company and in oral statements made by our officers and representatives from time to time. These forward-looking statements are intended to provide management’s current expectations or plans for our future operating and financial performance, based on assumptions currently believed to be valid. They can be identified by the use of words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “would,” “could,” “will” & other words of similar meaning in connection with a discussion of future operating or financial performance. Examples of forward-looking statements include, among others, statements relating to future sales, earnings, cash flows, results of operations, uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and other factors that may cause the Company’s actual results and financial condition to differ materially from those expressed or implied in the forward-looking statements. Such risks, uncertainties and other factors include, among others such as, but not limited to economic conditions, changes in the laws or regulations, demand for products and services of the company, the effects of competition and other factors that could cause actual results to differ materially from those projected or represented in the forward-looking statements. Any forward-looking information provided in this release should be considered w/ these factors in mind. We assume no obligation to update any forward-looking statements contained in this report.

Source: https://otcprwire.com/cyios-corps-receives-approval-to-sell-its-sanitizer-products-on-amazon-com/

Continue Reading

Biotechnology

Umbra Companies, Inc. Announces the Acquisition of H2O Processing

Avatar

Published

on

Tampa, FL, November 19, 2020 – OTC PR WIRE – Umbra Companies, Inc. (OTC: UCIX) announced today that it has initiated the acquisition of the Denver, Colorado based manufacturer of water treatment components company H2O Processing.

Chief Executive Officer, Alex Umbra commented, “H2O represents an evolution in water treatment technology commensurate with the growing environmental demands of modern times. What Stan and his team at H2O have developed is exceptionally dynamic and will result in a paradigm shift within the segment. This addition to our suite of companies supports our commitment to building value within our subsidiary structure and delivering improved shareholder value”.

H2O Processing is a manufacturing, research and engineering company, that has been operating within the water treatment space for 30 years in varying capacities. With an expanding portfolio of intellectual property, the H2O team has just recently begun its expansion into a full-provider and manufacturer of mobile on-site and fixed water treatment platforms.

The company’s mobile water treatment platform concluded field testing and certification within the past five years and has been awarded the only state-wide permit in all 77 counties within Oklahoma to treat deleterious water to non-deleterious water. The mobile platforms are fully automated and can be managed remotely by either H2O Processing from their headquarters in Denver or managed by the customers onsite team. The mobile platform is ready for commercial production and introduction into the market.

H2O Processing CEO stated, “we are aware of more than 2 trillion gallons of water that need to be treated in the United States daily.  This is a tremendous market that will require new water treatment equipment on a large scale.  We want to be in a position to supply this equipment with our associate company Processing Engineering, Inc so that we can further enhance our relationship with UCI. This path forward will allow H2O the capability of meeting the future demands as a “green” company”.

For more information about H2O Processing go here: https://h2otechnologiesinc.com/

About Umbra Companies, Inc.:

The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UCI is an investment holding company that invests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UCI subsidiaries. For more information visit www.umbracompanies.com

NEITHER THE SECURITIES EXCHANGE COMMISION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Forward-Looking Information

This news release may include “forward-looking statements” including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Companies, Inc. including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Risks and uncertainties about Umbra Companies, Inc. business are more fully discussed in the company’s disclosure materials, including its MD&A, filed with the securities regulatory authorities in Canada and available at www.sedar.com and readers are urged to read these materials. Umbra Companies, Inc. does not assume the obligation to update any forward-looking statement, except as required by applicable law.

Contact:

info@umbracompanies.com

Source: https://otcprwire.com/umbra-companies-inc-announces-the-acquisition-of-h2o-processing/

Continue Reading

Bioengineer

Newly discovered enzyme helps make valuable bioactive saponins

Avatar

Published

on

Osaka University-led research team discovers new enzyme, opening novel routes for producing a family of valuable chemicals with medical and food uses

Osaka, Japan – Many plants, including legumes, make naturally occurring chemicals called saponins. For example, the medicinal plant licorice produces the saponin glycyrrhizin, a potent natural sweetener that also has antiviral and other pharmacological activity. Soyasaponins, found in soybeans, have anticarcinogenic and antioxidant properties.

But exactly how plants make these useful products was unclear. Now a research team at Osaka University, in collaboration with National Agriculture and Food Research Organization (NARO), RIKEN, and Chiba University, has uncovered a vital link in the complex biochemical pathway for saponin synthesis. Their discovery paves the way for improving the commercial production of these high-value products. The team recently published the study in Nature Communications.

Osaka University researchers Soo Yeon Chung and Hikaru Seki, with collaborators in NARO (Masao Ishimoto et al.), RIKEN, and Chiba University, studied co-expression gene network of saponin synthesis using technologies including gene cloning and sequence comparisons, coupled with biochemical analyses in mutants and genetically modified plants of a model legume species. They discovered a new enzyme in the CSyGT family that are similar in structure to the enzymes producing cellulose in plant cell walls. Unexpectedly, they showed that the new member of the family was responsible for a key step in saponin synthesis, where a sugar molecule is attached to the triterpenoid backbone. This discovery challenged the generally accepted view that a different class of enzyme was probably involved in this step.

They went on to insert the gene for the newly discovered CSyGT enzyme, along with genes for other steps in the biochemical pathway, into yeast cells. The engineered cells successfully produced glycyrrhizin from simple sugars, indicating a potential route for industrial manufacture of valuable saponins by growing yeast cells on a large scale.

“Our multi-disciplinary team showed, for the first time, that this type of enzyme is important in saponin synthesis,” says corresponding author Toshiya Muranaka. “Our results fill a gap in previous knowledge and also challenge the accepted view of how this pathway for biosynthesis operates.”

“We showed that yeast cells can make glycyrrhizin when we insert the necessary plant genes,” explains Chung. “This offers the prospect of new ways to produce these valuable substances commercially, and to generate completely novel types of saponin that might have further beneficial applications in medicine or the food industry.” Seki adds, “producing the chemicals in cell cultures would also reduce the need to deplete natural plant resources and so help to meet the vitally important Sustainable Development Goals.”

###

The article, “A cellulose synthase-derived enzyme catalyses 3-O-glucuronosylation in saponin biosynthesis,” was published in Nature Communications at DOI: https://doi.org/10.1038/s41467-020-19399-0

About Osaka University

Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan’s leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world, being named Japan’s most innovative university in 2015 (Reuters 2015 Top 100) and one of the most innovative institutions in the world in 2017 (Innovative Universities and the Nature Index Innovation 2017). Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation.

Website: https://resou.osaka-u.ac.jp/en/top

Source: https://bioengineer.org/newly-discovered-enzyme-helps-make-valuable-bioactive-saponins/

Continue Reading
Energy9 hours ago

Ballard Closes US$402.5 Million Bought Deal Offering of Common Shares

Energy9 hours ago

Lithium-ion Battery Market Size USD 129.3 Billion By 2027 At A CAGR of 18.0% | Valuates Reports

Energy9 hours ago

CBAK Energy and Kandi Group Signed Supply Framework Agreement

Energy10 hours ago

Level Sensors Market worth $6.1 billion by 2025 – Exclusive Report by MarketsandMarkets™

Energy10 hours ago

Rescheduling of Work Commitments in Corentyne Block, Guyana

Cyber Security11 hours ago

Technological Innovations at the Tokyo Olympics

Gaming14 hours ago

The Basics: Popular Casino Games You Should Play

Press Releases15 hours ago

The International Vaccine Institute Supports a Global Campaign to Reduce the Spread of Covid-19

Esports16 hours ago

T1 re-signs top laner Canna, extends contract until 2022

Energy16 hours ago

JinkoSolar to Report Third Quarter 2020 Results on December 7, 2020

Energy16 hours ago

EWPG Holding AB: Interim report for the period 1 January – 30 September 2020

Esports17 hours ago

Khan joins DAMWON as team’s new top laner

Cyber Security18 hours ago

Different ways tech plays a key role in securing igaming platforms

Energy22 hours ago

LONGi suministra 273MW de sus módulos solares a la mayor planta solar del Sureste de Asia

Ecommerce23 hours ago

ADvendio Celebrates 10 Years of Product Excellence and Growth

Esports23 hours ago

Super Smash Bros. Melee Slippi mod launches broadcast feature early in response to #FreeMelee

Esports23 hours ago

The 7 best low-back gaming chairs

Denmark
Esports24 hours ago

Heroic move past Endpoint in BLAST Premier Showdown

Esports1 day ago

Na’Vi brings Mag back from inactive roster to coach Dota 2 team

Esports1 day ago

Fantasy games live for DreamHack Masters Winter and Flashpoint 2 playoffs

Energy1 day ago

Worldwide Hybrid Diesel Genset Industry to 2026 – Key Drivers and Restraints

Energy1 day ago

The Neutrino Energy Group Transcends the Theoretical to Transform Practical Energy Use Worldwide

Esports1 day ago

How to activate crossplay on Rainbow Six Siege

Esports1 day ago

Pokémon teases 25th-anniversary celebration during Macy’s Thanksgiving Day Parade

Energy1 day ago

ChemPoint es seleccionado como distribuidor de los productos de Soluciones Especializadas de DuPont para México

Esports1 day ago

Apex Legends Dev Believes Wattson Isn’t ‘Useless’

Esports1 day ago

Horizon Voice Actor Shows What it Was Like to Record During the Pandemic

United States
Esports1 day ago

Liquid edge past MAD Lions in BLAST Premier Fall Showdown

Energy1 day ago

Europe Excavator Market Outlook Report 2020-2025 Featuring Prominent Players – Caterpillar, CNH, John Deere, Kobelco, Liebherr

Esports1 day ago

League’s original 17 champions and how different they were 11 years ago

Trending